<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378391</url>
  </required_header>
  <id_info>
    <org_study_id>H4S-PL-O067</org_study_id>
    <nct_id>NCT00378391</nct_id>
  </id_info>
  <brief_title>European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry</brief_title>
  <official_title>European Registry on Patients With ST-Elevation MI Transferred for Mechanical Reperfusion (PCI)With a Special Focus on Upstream Use of Abciximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Medical Research in Krakow, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jagiellonian University</source>
  <brief_summary>
    <textblock>
      EUROTRANSFER Registry is a prospective, international, web-based European Registry on&#xD;
      Patients with ST-Elevation MI Transferred for Mechanical Reperfusion (PCI) with a Special&#xD;
      Focus on Upstream Use of Abciximab.&#xD;
&#xD;
      This registry is designed to collect data on approximately 1800 patients during a 12 month&#xD;
      enrollment period in up to 20 interventional cardiology centres with hospital transfer&#xD;
      networks from all over Europe.&#xD;
&#xD;
      Analysis of this registry should allow to monitor transfer timelines of patients arriving to&#xD;
      the cath-lab from the regional hospital with or without upstream start of abciximab and&#xD;
      scheduled for mechanical reperfusion (PCI) as well as to monitor regional differences across&#xD;
      Europe in regard to the impact that time of various stages of the treatment chain may have on&#xD;
      clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date>February 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>1800</enrollment>
  <condition>ST-Elevation Myocardial Infarction</condition>
  <condition>Acute Coronary Syndrome</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PATIENTS:&#xD;
&#xD;
          -  All consecutive STEMI patients &gt;=18years arriving to the Cath Lab hospital (invasive&#xD;
             facility center) from transfer.&#xD;
&#xD;
               -  Transfer with respect to this registry is defined as patients that reach the Cath&#xD;
                  Lab hospital:&#xD;
&#xD;
                    1. transferred from a surrounding regional community hospitals that the Cath&#xD;
                       Lab hospital has an established referral pattern with or&#xD;
&#xD;
                    2. after being picked-up by an ambulance which is equipped/staffed to provide&#xD;
                       specific medical therapy (like prehospital thrombolysis or upstream&#xD;
                       abciximab). Usually these have a physician or specifically trained nurse on&#xD;
                       board.&#xD;
&#xD;
                       CENTRES:&#xD;
&#xD;
               -  Provide 24 hour/7 days on duty PCI service.&#xD;
&#xD;
               -  Has an established regional hospital referral network with &gt;=8 patients/month&#xD;
                  arriving from transfer (as defined above).&#xD;
&#xD;
               -  A rate of &gt;=10% of these transfer patients who receive upstream abciximab before&#xD;
                  or during transfer to the Cath Lab hospital. Start of abciximab in the ER or CCU&#xD;
                  of the Cath Lab hospital will not be considered as upstream start of abciximab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who arrive to the Cath Lab from other pathways than those specified above (a.&#xD;
             and b.), e.g. those who come by ambulances that do not provide specific medical&#xD;
             therapy or arrive directly to the ER of the Cath Lab hospital by own feet/car will not&#xD;
             be included in this registry.&#xD;
&#xD;
          -  Patients from controlled clinical trials shall be included as long as their actual&#xD;
             treatment is fully known. Thus, participants from randomized trials with blinded&#xD;
             treatment cannot be included in this registry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariusz Dudek, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiac Catheterization Laboratories, Jagiellonian University Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zbigniew Siudak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiac Catheterization Laboratories, Jagiellonian University Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lukasz Partyka, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>KCRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH</name>
      <address>
        <city>Villingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Donato Hospital</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale G.Pasquinucci</name>
      <address>
        <city>Massa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Maria Nuova Hospital Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Maria di Ca Foncello</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Catheterization Laboratories Jagiellonian University Medical College, University Hospital</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interventional Cardiology, John Paul II Hospital</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki w Przemyslu</name>
      <address>
        <city>Przemysl</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital im. Szczeklika Tarnow</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo</name>
      <address>
        <city>Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.eurotransfer.org</url>
    <description>registry homepage</description>
  </link>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>September 19, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2006</study_first_posted>
  <last_update_submitted>June 19, 2007</last_update_submitted>
  <last_update_submitted_qc>June 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2007</last_update_posted>
  <keyword>ST-Elevation Myocardial Infarction</keyword>
  <keyword>upstream abciximab</keyword>
  <keyword>guideline adherence</keyword>
  <keyword>hospital networking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

